Boris Draznin
Concepts (591)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin | 98 | 2025 | 2399 | 4.320 |
Why?
| | Hyperglycemia | 11 | 2025 | 346 | 3.320 |
Why?
| | Diabetes Mellitus | 15 | 2021 | 1033 | 3.230 |
Why?
| | Insulin Resistance | 32 | 2013 | 1201 | 2.660 |
Why?
| | Phosphatidylinositol 3-Kinases | 17 | 2012 | 365 | 2.160 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 23 | 2006 | 267 | 2.060 |
Why?
| | Adipocytes | 13 | 2008 | 218 | 1.850 |
Why?
| | Receptor, Insulin | 26 | 2003 | 105 | 1.820 |
Why?
| | Hypoglycemic Agents | 16 | 2025 | 1281 | 1.700 |
Why?
| | Blood Glucose | 26 | 2025 | 2180 | 1.690 |
Why?
| | Diabetes Mellitus, Type 2 | 18 | 2025 | 2512 | 1.670 |
Why?
| | Alkyl and Aryl Transferases | 14 | 2003 | 53 | 1.640 |
Why?
| | Insulin, Long-Acting | 4 | 2020 | 63 | 1.470 |
Why?
| | Hyperinsulinism | 11 | 2009 | 121 | 1.290 |
Why?
| | Calcium | 21 | 2007 | 1197 | 1.110 |
Why?
| | Protein Prenylation | 11 | 2006 | 34 | 1.020 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2007 | 444 | 1.020 |
Why?
| | Adipose Tissue | 19 | 2007 | 629 | 0.970 |
Why?
| | Phosphorylation | 32 | 2013 | 1756 | 0.860 |
Why?
| | Insulin Receptor Substrate Proteins | 15 | 2013 | 59 | 0.830 |
Why?
| | Signal Transduction | 25 | 2012 | 5065 | 0.830 |
Why?
| | Muscle, Skeletal | 11 | 2012 | 1707 | 0.820 |
Why?
| | Hospitalization | 6 | 2025 | 2195 | 0.810 |
Why?
| | Rats | 69 | 2007 | 5628 | 0.790 |
Why?
| | Obesity | 15 | 2013 | 2975 | 0.680 |
Why?
| | Cytosol | 16 | 1994 | 226 | 0.680 |
Why?
| | Insulin Glargine | 4 | 2014 | 84 | 0.680 |
Why?
| | Monosaccharide Transport Proteins | 9 | 2003 | 48 | 0.670 |
Why?
| | Epidemics | 1 | 2021 | 87 | 0.650 |
Why?
| | Inpatients | 3 | 2013 | 499 | 0.630 |
Why?
| | Animals | 106 | 2013 | 36768 | 0.610 |
Why?
| | Glucose | 25 | 2006 | 1019 | 0.590 |
Why?
| | Proteins | 15 | 2001 | 1009 | 0.580 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2006 | 260 | 0.580 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 232 | 0.570 |
Why?
| | Enzyme Inhibitors | 13 | 2007 | 838 | 0.560 |
Why?
| | Dietary Fats | 5 | 2012 | 303 | 0.560 |
Why?
| | Platelet-Derived Growth Factor | 4 | 2003 | 91 | 0.550 |
Why?
| | Deoxyglucose | 10 | 2008 | 52 | 0.540 |
Why?
| | Endocrinology | 1 | 2018 | 79 | 0.530 |
Why?
| | Diabetes Mellitus, Type 1 | 8 | 2020 | 3709 | 0.520 |
Why?
| | 3T3-L1 Cells | 5 | 2008 | 35 | 0.510 |
Why?
| | Adiponectin | 4 | 2009 | 243 | 0.510 |
Why?
| | Insulin-Like Growth Factor I | 11 | 2005 | 316 | 0.490 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 84 | 0.490 |
Why?
| | Enteral Nutrition | 3 | 2013 | 200 | 0.490 |
Why?
| | Phosphoproteins | 10 | 2007 | 338 | 0.480 |
Why?
| | Protein Kinases | 3 | 2008 | 319 | 0.480 |
Why?
| | Somatostatin | 13 | 2001 | 61 | 0.470 |
Why?
| | Islets of Langerhans | 17 | 1991 | 803 | 0.470 |
Why?
| | Academic Medical Centers | 1 | 2018 | 497 | 0.460 |
Why?
| | Patient Care Planning | 1 | 2016 | 154 | 0.460 |
Why?
| | Triglycerides | 3 | 2012 | 524 | 0.460 |
Why?
| | Farnesyltranstransferase | 11 | 2009 | 35 | 0.460 |
Why?
| | Insulin, Isophane | 2 | 2013 | 21 | 0.460 |
Why?
| | Growth Hormone | 8 | 2007 | 101 | 0.450 |
Why?
| | 3T3 Cells | 13 | 2007 | 163 | 0.440 |
Why?
| | Rats, Inbred Strains | 26 | 1992 | 361 | 0.440 |
Why?
| | Dietary Carbohydrates | 3 | 2012 | 154 | 0.440 |
Why?
| | Phosphates | 3 | 2007 | 183 | 0.440 |
Why?
| | Humans | 68 | 2025 | 136783 | 0.440 |
Why?
| | Cells, Cultured | 25 | 2008 | 4194 | 0.430 |
Why?
| | Glucocorticoids | 2 | 2016 | 596 | 0.430 |
Why?
| | Guanosine Triphosphate | 12 | 2000 | 91 | 0.410 |
Why?
| | Muscle Proteins | 4 | 2012 | 229 | 0.410 |
Why?
| | Medically Uninsured | 1 | 2014 | 129 | 0.410 |
Why?
| | Kinetics | 24 | 2012 | 1668 | 0.400 |
Why?
| | Continuity of Patient Care | 2 | 2019 | 278 | 0.390 |
Why?
| | Liver | 15 | 2009 | 1938 | 0.390 |
Why?
| | Sirtuin 1 | 1 | 2012 | 30 | 0.380 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1568 | 0.380 |
Why?
| | Biphasic Insulins | 1 | 2011 | 3 | 0.380 |
Why?
| | Diabetes Mellitus, Experimental | 5 | 1992 | 193 | 0.380 |
Why?
| | Muscles | 3 | 2004 | 325 | 0.380 |
Why?
| | Enzyme Activation | 10 | 2008 | 813 | 0.380 |
Why?
| | Patient Preference | 1 | 2014 | 190 | 0.370 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 3 | 2007 | 57 | 0.370 |
Why?
| | Cystic Fibrosis | 2 | 2012 | 1104 | 0.370 |
Why?
| | Insulin Lispro | 1 | 2011 | 39 | 0.370 |
Why?
| | Decision Making | 2 | 2018 | 896 | 0.360 |
Why?
| | Cell Membrane | 18 | 2003 | 736 | 0.360 |
Why?
| | Patient Care Team | 1 | 2016 | 627 | 0.350 |
Why?
| | Methylprednisolone | 1 | 2011 | 85 | 0.350 |
Why?
| | Patient Admission | 1 | 2012 | 191 | 0.340 |
Why?
| | Thiazolidinediones | 2 | 2008 | 137 | 0.340 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 197 | 0.340 |
Why?
| | Mice | 28 | 2009 | 17731 | 0.340 |
Why?
| | Phosphoprotein Phosphatases | 4 | 1995 | 67 | 0.330 |
Why?
| | Atherosclerosis | 4 | 2019 | 415 | 0.330 |
Why?
| | Hospitals | 2 | 2013 | 677 | 0.330 |
Why?
| | Receptors, Cell Surface | 12 | 1986 | 386 | 0.330 |
Why?
| | Blotting, Western | 9 | 2012 | 1225 | 0.330 |
Why?
| | Epidermal Growth Factor | 6 | 1998 | 174 | 0.330 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2011 | 2045 | 0.330 |
Why?
| | Phosphoric Monoester Hydrolases | 4 | 1994 | 54 | 0.320 |
Why?
| | Pituitary Gland, Anterior | 5 | 1988 | 38 | 0.320 |
Why?
| | Medicaid | 1 | 2014 | 433 | 0.320 |
Why?
| | Male | 56 | 2025 | 67361 | 0.320 |
Why?
| | Biomarkers | 3 | 2020 | 4158 | 0.320 |
Why?
| | Quality Improvement | 2 | 2018 | 1152 | 0.320 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2001 | 429 | 0.310 |
Why?
| | rhoA GTP-Binding Protein | 4 | 2003 | 86 | 0.310 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 16 | 0.310 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 111 | 0.310 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2001 | 145 | 0.300 |
Why?
| | Gene Expression Regulation, Enzymologic | 4 | 2005 | 284 | 0.300 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2008 | 14 | 0.300 |
Why?
| | MAP Kinase Signaling System | 3 | 2006 | 321 | 0.300 |
Why?
| | DNA-Binding Proteins | 5 | 2004 | 1500 | 0.300 |
Why?
| | Blood Glucose Self-Monitoring | 3 | 2025 | 638 | 0.290 |
Why?
| | Cyclic AMP | 9 | 1993 | 234 | 0.290 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 925 | 0.290 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1997 | 182 | 0.290 |
Why?
| | Algorithms | 1 | 2016 | 1686 | 0.290 |
Why?
| | Adult | 20 | 2025 | 37616 | 0.290 |
Why?
| | Mitochondrial Diseases | 1 | 2008 | 91 | 0.280 |
Why?
| | Transfection | 9 | 2008 | 945 | 0.280 |
Why?
| | Diabetic Angiopathies | 2 | 2007 | 258 | 0.280 |
Why?
| | Leukocytes | 2 | 2006 | 312 | 0.270 |
Why?
| | Pregnancy Proteins | 2 | 2005 | 36 | 0.270 |
Why?
| | Early Growth Response Protein 1 | 2 | 2006 | 27 | 0.260 |
Why?
| | Androstadienes | 5 | 2008 | 107 | 0.260 |
Why?
| | Phosphoserine | 1 | 2006 | 34 | 0.260 |
Why?
| | src Homology Domains | 2 | 2003 | 41 | 0.260 |
Why?
| | Organophosphonates | 2 | 1997 | 92 | 0.260 |
Why?
| | Female | 30 | 2025 | 72840 | 0.260 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 62 | 0.260 |
Why?
| | Middle Aged | 17 | 2025 | 33200 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1323 | 0.250 |
Why?
| | Glyburide | 6 | 1988 | 32 | 0.250 |
Why?
| | Cytoplasmic Granules | 6 | 1986 | 93 | 0.250 |
Why?
| | Food Deprivation | 1 | 2006 | 25 | 0.250 |
Why?
| | Fasting | 7 | 2005 | 278 | 0.250 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 54 | 0.250 |
Why?
| | Mitogens | 3 | 2001 | 61 | 0.240 |
Why?
| | Fatty Acids | 2 | 2012 | 444 | 0.240 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 255 | 0.240 |
Why?
| | Drug Synergism | 6 | 2003 | 378 | 0.240 |
Why?
| | RNA, Messenger | 8 | 2006 | 2831 | 0.240 |
Why?
| | Transferases | 4 | 1997 | 33 | 0.230 |
Why?
| | Transcription Factors | 5 | 2004 | 1714 | 0.230 |
Why?
| | In Vitro Techniques | 15 | 2003 | 1089 | 0.230 |
Why?
| | Adaptor Proteins, Vesicular Transport | 3 | 2001 | 45 | 0.230 |
Why?
| | Cell Division | 5 | 2009 | 796 | 0.230 |
Why?
| | Diet, Reducing | 1 | 2005 | 88 | 0.230 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 42 | 0.230 |
Why?
| | Diabetes Complications | 2 | 2019 | 226 | 0.230 |
Why?
| | Diabetes, Gestational | 2 | 2006 | 316 | 0.230 |
Why?
| | Protein Subunits | 4 | 2008 | 239 | 0.220 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 37 | 0.220 |
Why?
| | Fetal Blood | 1 | 2006 | 327 | 0.220 |
Why?
| | Cell Line | 12 | 2008 | 2836 | 0.210 |
Why?
| | Protein Kinase C | 3 | 1996 | 260 | 0.210 |
Why?
| | ras Proteins | 2 | 2009 | 151 | 0.210 |
Why?
| | Lysophospholipids | 2 | 2001 | 80 | 0.210 |
Why?
| | Garlic | 1 | 2003 | 4 | 0.210 |
Why?
| | Sulfinic Acids | 1 | 2003 | 7 | 0.200 |
Why?
| | Up-Regulation | 1 | 2006 | 843 | 0.200 |
Why?
| | Cell Nucleus | 3 | 1995 | 614 | 0.200 |
Why?
| | Metabolic Syndrome | 3 | 2013 | 354 | 0.190 |
Why?
| | Aged | 9 | 2025 | 23729 | 0.190 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 2 | 1992 | 49 | 0.180 |
Why?
| | Breast Neoplasms | 3 | 2003 | 2239 | 0.180 |
Why?
| | Caloric Restriction | 2 | 2012 | 123 | 0.180 |
Why?
| | Plant Extracts | 1 | 2003 | 200 | 0.180 |
Why?
| | Cell Cycle | 2 | 2001 | 601 | 0.170 |
Why?
| | Growth Substances | 2 | 1998 | 147 | 0.170 |
Why?
| | Angiotensin II | 1 | 2000 | 99 | 0.170 |
Why?
| | Nitrendipine | 7 | 1993 | 13 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2001 | 173 | 0.160 |
Why?
| | Intensive Care Units | 1 | 2025 | 802 | 0.160 |
Why?
| | Cattle | 6 | 2007 | 981 | 0.160 |
Why?
| | Weight Loss | 1 | 2005 | 775 | 0.160 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 2 | 1996 | 45 | 0.160 |
Why?
| | Deoxy Sugars | 2 | 1989 | 2 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2603 | 0.160 |
Why?
| | Oxidative Stress | 1 | 2006 | 1309 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2021 | 247 | 0.150 |
Why?
| | Receptor, IGF Type 1 | 1 | 1998 | 65 | 0.150 |
Why?
| | GTP-Binding Proteins | 1 | 1999 | 161 | 0.150 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 393 | 0.140 |
Why?
| | Serine | 2 | 2008 | 141 | 0.140 |
Why?
| | Aging | 5 | 1992 | 1861 | 0.140 |
Why?
| | Cations | 1 | 1998 | 85 | 0.140 |
Why?
| | Receptors, Somatostatin | 11 | 1986 | 25 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 306 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2003 | 313 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 1996 | 171 | 0.130 |
Why?
| | Models, Organizational | 1 | 2018 | 146 | 0.130 |
Why?
| | Pilot Projects | 2 | 2014 | 1697 | 0.130 |
Why?
| | Young Adult | 6 | 2020 | 13126 | 0.130 |
Why?
| | Time Factors | 7 | 2006 | 6792 | 0.130 |
Why?
| | Oncogene Protein v-akt | 2 | 2008 | 24 | 0.130 |
Why?
| | NF-kappa B | 1 | 2000 | 691 | 0.130 |
Why?
| | Life Style | 1 | 2019 | 484 | 0.130 |
Why?
| | Exocytosis | 5 | 1988 | 89 | 0.130 |
Why?
| | Fibroblasts | 6 | 2001 | 989 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 627 | 0.130 |
Why?
| | 1-Methyl-3-isobutylxanthine | 6 | 1986 | 24 | 0.130 |
Why?
| | Hypertension | 3 | 2019 | 1284 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2016 | 15564 | 0.120 |
Why?
| | Potassium | 7 | 1992 | 147 | 0.120 |
Why?
| | Recombinant Proteins | 5 | 2001 | 1354 | 0.120 |
Why?
| | Swine, Miniature | 2 | 2013 | 82 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 973 | 0.120 |
Why?
| | Calcium-Transporting ATPases | 2 | 1993 | 40 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 152 | 0.120 |
Why?
| | Mice, Obese | 2 | 2009 | 66 | 0.120 |
Why?
| | Somatomedins | 5 | 1981 | 27 | 0.120 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 160 | 0.120 |
Why?
| | Glycogen Synthase | 2 | 1991 | 7 | 0.120 |
Why?
| | Placenta Growth Factor | 2 | 2005 | 24 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 5 | 2006 | 2481 | 0.110 |
Why?
| | Glucose Transporter Type 4 | 3 | 2003 | 40 | 0.110 |
Why?
| | United States | 5 | 2021 | 14660 | 0.110 |
Why?
| | Rats, Zucker | 2 | 2007 | 34 | 0.110 |
Why?
| | Thinness | 2 | 2012 | 91 | 0.110 |
Why?
| | Fatty Acid Synthases | 2 | 2006 | 24 | 0.110 |
Why?
| | Inulin | 1 | 1993 | 7 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2018 | 10764 | 0.110 |
Why?
| | Point-of-Care Systems | 1 | 2015 | 163 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 267 | 0.100 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 364 | 0.100 |
Why?
| | ras Guanine Nucleotide Exchange Factors | 5 | 1996 | 8 | 0.100 |
Why?
| | GRB2 Adaptor Protein | 5 | 2001 | 13 | 0.100 |
Why?
| | Guanosine Diphosphate | 4 | 1997 | 20 | 0.100 |
Why?
| | Education, Medical | 1 | 1996 | 260 | 0.100 |
Why?
| | Mice, Transgenic | 4 | 2007 | 2162 | 0.100 |
Why?
| | Insulin Antagonists | 2 | 2008 | 8 | 0.100 |
Why?
| | Guanine Nucleotide Exchange Factors | 5 | 1996 | 66 | 0.100 |
Why?
| | Cricetinae | 3 | 2001 | 288 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2018 | 777 | 0.100 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 154 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 107 | 0.090 |
Why?
| | Models, Biological | 4 | 2007 | 1769 | 0.090 |
Why?
| | Phospholipases A | 1 | 1991 | 102 | 0.090 |
Why?
| | ras GTPase-Activating Proteins | 3 | 1996 | 15 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4018 | 0.090 |
Why?
| | ErbB Receptors | 4 | 1996 | 613 | 0.090 |
Why?
| | Transcription, Genetic | 3 | 2012 | 1453 | 0.090 |
Why?
| | PPAR gamma | 1 | 2012 | 182 | 0.090 |
Why?
| | Flavonoids | 2 | 2004 | 83 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 156 | 0.090 |
Why?
| | GTPase-Activating Proteins | 3 | 1996 | 82 | 0.090 |
Why?
| | Prospective Studies | 3 | 2025 | 7583 | 0.090 |
Why?
| | Isoenzymes | 1 | 1991 | 304 | 0.090 |
Why?
| | Chromones | 2 | 2004 | 44 | 0.090 |
Why?
| | Membrane Proteins | 2 | 1996 | 1162 | 0.090 |
Why?
| | Luciferases | 2 | 2000 | 150 | 0.080 |
Why?
| | Oncogene Protein p21(ras) | 3 | 1994 | 16 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 976 | 0.080 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1990 | 68 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2009 | 5744 | 0.080 |
Why?
| | RNA | 2 | 2009 | 924 | 0.080 |
Why?
| | Morpholines | 2 | 2004 | 121 | 0.080 |
Why?
| | Reference Values | 5 | 2002 | 817 | 0.080 |
Why?
| | Energy Metabolism | 3 | 2012 | 918 | 0.080 |
Why?
| | Ion Channels | 2 | 1988 | 132 | 0.080 |
Why?
| | Genes, Reporter | 2 | 2000 | 268 | 0.080 |
Why?
| | Genes | 1 | 1990 | 230 | 0.080 |
Why?
| | Diet | 3 | 2013 | 1273 | 0.080 |
Why?
| | Critical Illness | 1 | 2015 | 807 | 0.080 |
Why?
| | Tyrosine | 2 | 2008 | 222 | 0.080 |
Why?
| | Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2008 | 5 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2001 | 953 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 434 | 0.080 |
Why?
| | Telemedicine | 1 | 2018 | 847 | 0.080 |
Why?
| | Aorta | 1 | 1991 | 417 | 0.080 |
Why?
| | Cyclosporins | 1 | 1988 | 76 | 0.080 |
Why?
| | Cell Movement | 2 | 2003 | 969 | 0.070 |
Why?
| | CHO Cells | 2 | 2001 | 160 | 0.070 |
Why?
| | Verapamil | 4 | 1988 | 41 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2012 | 512 | 0.070 |
Why?
| | Patient Readmission | 1 | 2014 | 695 | 0.070 |
Why?
| | Biological Transport | 3 | 1998 | 411 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7569 | 0.070 |
Why?
| | Erectile Dysfunction | 1 | 1988 | 40 | 0.070 |
Why?
| | Liver Glycogen | 3 | 1986 | 17 | 0.070 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 326 | 0.070 |
Why?
| | Calcium Channels | 1 | 1988 | 159 | 0.070 |
Why?
| | PPAR alpha | 1 | 2007 | 58 | 0.070 |
Why?
| | Fenofibrate | 1 | 2007 | 28 | 0.070 |
Why?
| | Mevalonic Acid | 2 | 1997 | 13 | 0.070 |
Why?
| | Swine | 3 | 2013 | 773 | 0.070 |
Why?
| | Parathyroid Hormone | 3 | 1993 | 108 | 0.070 |
Why?
| | Lovastatin | 3 | 1996 | 37 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 27 | 0.070 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.070 |
Why?
| | Farnesol | 2 | 1997 | 6 | 0.070 |
Why?
| | Patient Discharge | 1 | 2014 | 896 | 0.070 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2013 | 204 | 0.070 |
Why?
| | Exercise Tolerance | 1 | 2009 | 279 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2001 | 663 | 0.070 |
Why?
| | Eating | 1 | 1990 | 378 | 0.070 |
Why?
| | Gene Expression | 1 | 2012 | 1499 | 0.070 |
Why?
| | Hypolipidemic Agents | 1 | 2007 | 92 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2011 | 443 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 1988 | 143 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 1996 | 45 | 0.070 |
Why?
| | Cell Fusion | 1 | 1986 | 52 | 0.070 |
Why?
| | Bucladesine | 3 | 1992 | 26 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 296 | 0.060 |
Why?
| | Adenosine Triphosphate | 3 | 1993 | 486 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 21 | 0.060 |
Why?
| | Organophosphorus Compounds | 2 | 1997 | 78 | 0.060 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 621 | 0.060 |
Why?
| | Microscopy, Electron | 4 | 1989 | 432 | 0.060 |
Why?
| | Coated Pits, Cell-Membrane | 1 | 1985 | 4 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2005 | 2999 | 0.060 |
Why?
| | Macromolecular Substances | 3 | 1996 | 229 | 0.060 |
Why?
| | Heart | 1 | 2009 | 656 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1455 | 0.060 |
Why?
| | Interleukin-1 | 1 | 1989 | 963 | 0.060 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 3 | 2001 | 12 | 0.060 |
Why?
| | Shc Signaling Adaptor Proteins | 3 | 2001 | 12 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2008 | 412 | 0.060 |
Why?
| | Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2006 | 167 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 282 | 0.060 |
Why?
| | Theophylline | 1 | 1985 | 67 | 0.060 |
Why?
| | Body Weight | 6 | 2002 | 981 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 185 | 0.060 |
Why?
| | Basal Metabolism | 1 | 2005 | 60 | 0.060 |
Why?
| | Peptides | 2 | 1981 | 980 | 0.060 |
Why?
| | Hemodynamics | 1 | 2009 | 1110 | 0.060 |
Why?
| | Risk | 1 | 2007 | 904 | 0.060 |
Why?
| | Endosomes | 1 | 1985 | 136 | 0.050 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 11 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 3 | 1993 | 434 | 0.050 |
Why?
| | Blotting, Northern | 3 | 1995 | 199 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 1990 | 895 | 0.050 |
Why?
| | Colorado | 1 | 2014 | 4491 | 0.050 |
Why?
| | Arachidonic Acids | 3 | 1988 | 62 | 0.050 |
Why?
| | Phosphorus Radioisotopes | 2 | 1993 | 30 | 0.050 |
Why?
| | Breast | 1 | 2003 | 150 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 2 | 1996 | 646 | 0.050 |
Why?
| | Pregnancy | 3 | 2006 | 6731 | 0.050 |
Why?
| | Energy Intake | 2 | 2005 | 484 | 0.050 |
Why?
| | Hypothyroidism | 2 | 1980 | 71 | 0.050 |
Why?
| | Placental Hormones | 1 | 2002 | 4 | 0.050 |
Why?
| | Streptozocin | 2 | 1992 | 20 | 0.050 |
Why?
| | Cyclin D | 1 | 2001 | 9 | 0.050 |
Why?
| | Cyclin E | 1 | 2001 | 25 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2003 | 349 | 0.050 |
Why?
| | Disease Models, Animal | 4 | 2013 | 4279 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2001 | 1980 | 0.040 |
Why?
| | Fetal Weight | 1 | 2001 | 56 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 867 | 0.040 |
Why?
| | Cyclins | 1 | 2001 | 91 | 0.040 |
Why?
| | Starvation | 1 | 1981 | 22 | 0.040 |
Why?
| | Carrier Proteins | 3 | 1980 | 768 | 0.040 |
Why?
| | Colforsin | 3 | 1991 | 53 | 0.040 |
Why?
| | Nitric Oxide Synthase | 1 | 2001 | 240 | 0.040 |
Why?
| | Calmodulin | 3 | 1986 | 76 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2003 | 436 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2000 | 378 | 0.040 |
Why?
| | Serum Response Factor | 1 | 2000 | 33 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2001 | 408 | 0.040 |
Why?
| | Glucosamine | 1 | 2000 | 13 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 1 | 2001 | 165 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 132 | 0.040 |
Why?
| | Response Elements | 1 | 2000 | 91 | 0.040 |
Why?
| | Lysosomes | 1 | 1981 | 142 | 0.040 |
Why?
| | Adenoviridae | 1 | 2001 | 193 | 0.040 |
Why?
| | Hypopituitarism | 1 | 1980 | 15 | 0.040 |
Why?
| | Glycation End Products, Advanced | 1 | 2000 | 82 | 0.040 |
Why?
| | Son of Sevenless Proteins | 2 | 1996 | 4 | 0.040 |
Why?
| | Fura-2 | 2 | 1991 | 12 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2000 | 298 | 0.040 |
Why?
| | Leptin | 1 | 2001 | 234 | 0.040 |
Why?
| | DNA Replication | 1 | 2001 | 238 | 0.040 |
Why?
| | Arachidonic Acid | 3 | 1988 | 120 | 0.040 |
Why?
| | Disease Progression | 1 | 2007 | 2750 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 219 | 0.040 |
Why?
| | Muscle Denervation | 1 | 1999 | 8 | 0.040 |
Why?
| | Aurothioglucose | 1 | 1999 | 7 | 0.040 |
Why?
| | Clenbuterol | 1 | 1999 | 4 | 0.040 |
Why?
| | Endocrinologists | 1 | 2019 | 13 | 0.040 |
Why?
| | rab3 GTP-Binding Proteins | 1 | 1999 | 5 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 1999 | 9 | 0.040 |
Why?
| | Body Composition | 3 | 2009 | 677 | 0.040 |
Why?
| | Ionomycin | 2 | 1989 | 23 | 0.040 |
Why?
| | Dogs | 1 | 2000 | 409 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2009 | 159 | 0.040 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 1998 | 79 | 0.040 |
Why?
| | Endothelial Growth Factors | 1 | 1998 | 64 | 0.040 |
Why?
| | Sheep | 1 | 2001 | 855 | 0.040 |
Why?
| | Lymphokines | 1 | 1998 | 131 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2019 | 120 | 0.040 |
Why?
| | Diabetic Neuropathies | 1 | 2019 | 93 | 0.040 |
Why?
| | Ethanol | 1 | 1983 | 608 | 0.040 |
Why?
| | Protein Phosphatase 2 | 2 | 1995 | 41 | 0.040 |
Why?
| | Binding Sites | 2 | 1996 | 1308 | 0.040 |
Why?
| | Prosencephalon | 2 | 1994 | 48 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 467 | 0.040 |
Why?
| | Half-Life | 1 | 1997 | 165 | 0.030 |
Why?
| | Magnesium | 1 | 1998 | 158 | 0.030 |
Why?
| | Physician's Role | 1 | 2019 | 206 | 0.030 |
Why?
| | Dinitrophenols | 3 | 1982 | 8 | 0.030 |
Why?
| | Growth Hormone-Releasing Hormone | 2 | 1988 | 24 | 0.030 |
Why?
| | Rats, Wistar | 1 | 1998 | 454 | 0.030 |
Why?
| | Phenytoin | 1 | 1977 | 21 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3272 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2019 | 189 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1996 | 6 | 0.030 |
Why?
| | Fetus | 1 | 2001 | 806 | 0.030 |
Why?
| | Immunosorbent Techniques | 1 | 1996 | 21 | 0.030 |
Why?
| | Second Messenger Systems | 1 | 1996 | 31 | 0.030 |
Why?
| | Accidental Falls | 1 | 2019 | 188 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1996 | 23 | 0.030 |
Why?
| | Protein Phosphatase 1 | 2 | 1993 | 33 | 0.030 |
Why?
| | Body Mass Index | 1 | 2005 | 2364 | 0.030 |
Why?
| | Oxygen Consumption | 2 | 2009 | 696 | 0.030 |
Why?
| | Prediabetic State | 1 | 2019 | 253 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 134 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 1998 | 544 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 1986 | 264 | 0.030 |
Why?
| | Genes, Immediate-Early | 1 | 1995 | 21 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2000 | 710 | 0.030 |
Why?
| | Immunoblotting | 1 | 1996 | 307 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 293 | 0.030 |
Why?
| | Immediate-Early Proteins | 1 | 1995 | 49 | 0.030 |
Why?
| | Off-Label Use | 1 | 2015 | 52 | 0.030 |
Why?
| | Research Support as Topic | 1 | 1996 | 118 | 0.030 |
Why?
| | Neurons | 2 | 1994 | 1583 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2006 | 6046 | 0.030 |
Why?
| | Glycogen | 1 | 1995 | 55 | 0.030 |
Why?
| | Trypsin | 2 | 1993 | 77 | 0.030 |
Why?
| | Phenotype | 1 | 2003 | 3199 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 623 | 0.030 |
Why?
| | Peptide Mapping | 1 | 1994 | 64 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1995 | 183 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2644 | 0.030 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 1994 | 11 | 0.030 |
Why?
| | ras-GRF1 | 1 | 1993 | 2 | 0.030 |
Why?
| | DNA | 2 | 1998 | 1458 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 268 | 0.030 |
Why?
| | Receptor, ErbB-2 | 1 | 1996 | 342 | 0.030 |
Why?
| | Chloroquine | 2 | 1986 | 52 | 0.030 |
Why?
| | Intracellular Membranes | 2 | 1985 | 84 | 0.030 |
Why?
| | Carbon Radioisotopes | 1 | 1993 | 34 | 0.030 |
Why?
| | Thapsigargin | 1 | 1993 | 20 | 0.030 |
Why?
| | Thionucleotides | 1 | 1993 | 35 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 1996 | 455 | 0.030 |
Why?
| | Terpenes | 1 | 1993 | 23 | 0.030 |
Why?
| | Mutation | 1 | 2004 | 3953 | 0.020 |
Why?
| | Phenols | 1 | 1993 | 100 | 0.020 |
Why?
| | Research | 1 | 1996 | 445 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 611 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 376 | 0.020 |
Why?
| | Hormones | 2 | 1984 | 142 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 2145 | 0.020 |
Why?
| | Phosphorylase a | 1 | 1992 | 1 | 0.020 |
Why?
| | Blood Pressure | 2 | 2009 | 1772 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 679 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1996 | 442 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1996 | 707 | 0.020 |
Why?
| | Okadaic Acid | 1 | 1991 | 14 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 194 | 0.020 |
Why?
| | Ethers, Cyclic | 1 | 1991 | 8 | 0.020 |
Why?
| | Vanadates | 1 | 1991 | 14 | 0.020 |
Why?
| | Mesocricetus | 1 | 1991 | 39 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 1991 | 80 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1992 | 150 | 0.020 |
Why?
| | Cadaverine | 2 | 1982 | 2 | 0.020 |
Why?
| | Densitometry | 1 | 1991 | 34 | 0.020 |
Why?
| | Calorimetry | 1 | 2012 | 69 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 1991 | 145 | 0.020 |
Why?
| | Wheat Germ Agglutinins | 1 | 1991 | 3 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Arteries | 1 | 2013 | 268 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 345 | 0.020 |
Why?
| | Sodium Fluoride | 2 | 1981 | 15 | 0.020 |
Why?
| | Sodium | 1 | 1992 | 214 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1262 | 0.020 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 15 | 0.020 |
Why?
| | Food | 1 | 1992 | 159 | 0.020 |
Why?
| | Membrane Potentials | 1 | 1991 | 283 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 60 | 0.020 |
Why?
| | Japan | 1 | 1990 | 116 | 0.020 |
Why?
| | Secretory Rate | 2 | 1987 | 16 | 0.020 |
Why?
| | Homozygote | 1 | 1990 | 203 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 495 | 0.020 |
Why?
| | Nonsuppressible Insulin-Like Activity | 2 | 1979 | 2 | 0.020 |
Why?
| | Sphingosine | 1 | 1989 | 46 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.020 |
Why?
| | Plethysmography | 1 | 2009 | 106 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1059 | 0.020 |
Why?
| | Trifluoperazine | 2 | 1987 | 4 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 130 | 0.020 |
Why?
| | Freeze Fracturing | 1 | 1988 | 4 | 0.020 |
Why?
| | Hydrostatic Pressure | 1 | 1988 | 18 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 5417 | 0.020 |
Why?
| | Puberty | 1 | 2009 | 146 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 1062 | 0.020 |
Why?
| | Freezing | 1 | 1988 | 91 | 0.020 |
Why?
| | Ethers | 1 | 1987 | 19 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 412 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2009 | 366 | 0.020 |
Why?
| | Egtazic Acid | 1 | 1987 | 40 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 436 | 0.020 |
Why?
| | Benzofurans | 1 | 1987 | 21 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 411 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 845 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 1987 | 168 | 0.020 |
Why?
| | Digitonin | 1 | 1986 | 5 | 0.020 |
Why?
| | Culture Techniques | 1 | 1986 | 81 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 625 | 0.020 |
Why?
| | Glyceraldehyde | 1 | 1985 | 2 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 659 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 513 | 0.020 |
Why?
| | Pronase | 1 | 1985 | 5 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 1986 | 80 | 0.020 |
Why?
| | Sonication | 1 | 1985 | 13 | 0.020 |
Why?
| | Heart Failure | 1 | 2019 | 2228 | 0.020 |
Why?
| | Adolescent | 4 | 2009 | 21463 | 0.020 |
Why?
| | Feedback | 1 | 1986 | 173 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1987 | 318 | 0.010 |
Why?
| | Urea | 1 | 1985 | 81 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1985 | 59 | 0.010 |
Why?
| | Golgi Apparatus | 1 | 1985 | 100 | 0.010 |
Why?
| | Heart Rate | 1 | 2009 | 823 | 0.010 |
Why?
| | Peptide Hydrolases | 1 | 1986 | 111 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1985 | 202 | 0.010 |
Why?
| | Biopsy | 1 | 1988 | 1126 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2009 | 778 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1985 | 329 | 0.010 |
Why?
| | Homeostasis | 1 | 1988 | 618 | 0.010 |
Why?
| | Organoids | 1 | 1986 | 111 | 0.010 |
Why?
| | Lipids | 1 | 2009 | 665 | 0.010 |
Why?
| | Gold | 1 | 1985 | 125 | 0.010 |
Why?
| | Motor Activity | 1 | 2009 | 719 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2108 | 0.010 |
Why?
| | Chick Embryo | 2 | 1994 | 130 | 0.010 |
Why?
| | Thyroxine | 2 | 1981 | 62 | 0.010 |
Why?
| | Endocytosis | 1 | 1984 | 168 | 0.010 |
Why?
| | Perfusion | 2 | 1981 | 211 | 0.010 |
Why?
| | 2,4-Dinitrophenol | 1 | 1982 | 9 | 0.010 |
Why?
| | Colchicine | 1 | 1982 | 23 | 0.010 |
Why?
| | Cycloheximide | 1 | 1982 | 55 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1982 | 77 | 0.010 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.010 |
Why?
| | Deuterium | 1 | 1982 | 98 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3537 | 0.010 |
Why?
| | Receptors, Somatomedin | 1 | 1981 | 4 | 0.010 |
Why?
| | Nutrition Disorders | 1 | 1981 | 23 | 0.010 |
Why?
| | Radioisotopes | 1 | 1981 | 31 | 0.010 |
Why?
| | Purine Nucleotides | 1 | 1981 | 12 | 0.010 |
Why?
| | Intracellular Fluid | 1 | 1981 | 27 | 0.010 |
Why?
| | Biotransformation | 1 | 1981 | 66 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 1980 | 79 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 1980 | 66 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1981 | 564 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1980 | 311 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 1988 | 5115 | 0.010 |
Why?
| | Growth Disorders | 1 | 1979 | 86 | 0.010 |
Why?
| | Inflammation | 1 | 2009 | 2834 | 0.010 |
Why?
| | 11-Hydroxycorticosteroids | 1 | 1977 | 1 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1996 | 38 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1995 | 34 | 0.010 |
Why?
| | Genes, fos | 1 | 1995 | 36 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1981 | 565 | 0.010 |
Why?
| | Child | 2 | 2009 | 21968 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 573 | 0.010 |
Why?
| | Neurites | 1 | 1994 | 48 | 0.010 |
Why?
| | Microinjections | 1 | 1994 | 86 | 0.010 |
Why?
| | Protein Binding | 1 | 1980 | 2223 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1994 | 185 | 0.010 |
Why?
| | Antibodies | 1 | 1994 | 412 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 2180 | 0.010 |
Why?
| | Cell Survival | 1 | 1994 | 1117 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 2903 | 0.010 |
Why?
| | Hydroxymercuribenzoates | 1 | 1987 | 1 | 0.000 |
Why?
| | Dantrolene | 1 | 1987 | 6 | 0.000 |
Why?
| | Oleic Acids | 1 | 1987 | 11 | 0.000 |
Why?
| | Lipoxygenase Inhibitors | 1 | 1987 | 37 | 0.000 |
Why?
| | Oleic Acid | 1 | 1987 | 40 | 0.000 |
Why?
| | Child, Preschool | 1 | 1980 | 11069 | 0.000 |
Why?
| | Membrane Fluidity | 1 | 1984 | 11 | 0.000 |
Why?
| | Diterpenes | 1 | 1984 | 31 | 0.000 |
Why?
| | Membrane Lipids | 1 | 1984 | 90 | 0.000 |
Why?
| | Glucagon | 1 | 1984 | 109 | 0.000 |
Why?
| | Adenine Nucleotides | 1 | 1982 | 23 | 0.000 |
Why?
| | Phospholipids | 1 | 1984 | 222 | 0.000 |
Why?
| | Adenosine Triphosphatases | 1 | 1982 | 165 | 0.000 |
Why?
| | Nephrectomy | 1 | 1981 | 168 | 0.000 |
Why?
| | Propylthiouracil | 1 | 1979 | 5 | 0.000 |
Why?
| | Hypophysectomy | 1 | 1979 | 15 | 0.000 |
Why?
| | Puromycin | 1 | 1979 | 10 | 0.000 |
Why?
| | Radioligand Assay | 1 | 1979 | 48 | 0.000 |
Why?
| | Kidney | 1 | 1981 | 1463 | 0.000 |
Why?
|
|
Draznin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|